

25W

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date  
7 April 2005 (07.04.2005)

PCT

(10) International Publication Number  
**WO 2005/030205 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/436**, 38/13, 31/365, 31/7048, 31/7052, A61P 27/02

(21) International Application Number:  
**PCT/US2004/030186**

(22) International Filing Date:  
16 September 2004 (16.09.2004)

(25) Filing Language:  
English

(26) Publication Language:  
English

(30) Priority Data:  
10/667,161 19 September 2003 (19.09.2003) US  
10/752,124 6 January 2004 (06.01.2004) US

(71) Applicant (for all designated States except US): MINU, L.L.C. [US/US]; 321 Miles Branch Road, Pittsboro, NC 27312 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): PEYMAN, Gholam, A. [US/US]; 8654 Pontchartrain Boulevard, Unit #1, New Orleans, LA 70124 (US).

(74) Agents: LYMAN, Beverly, A. et al.; Wood, Herron & Evans, L.L.P., 2700 Carew Tower, Cincinnati, OH 45202 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**WO 2005/030205 A1**

(54) Title: OCULAR SOLUTIONS CONTAINING A MACROLIDE ANTIBIOTIC AND/OR MYCOPHENOLIC ACID

(57) Abstract: Ocular solutions containing at least one macrolide antibiotic and/or mycophenolic acid provide anti-inflammatory, anti-cell proliferation, anti-cell migration, anti-angiogenesis, antimicrobial, and antifungal effects. The solution may be administered intraocularly after cataract surgery before inserting a replacement intraocular lens. The solution may be invasively administered, e.g., an irrigation or volume replacement solution containing at least one macrolide antibiotic such as tacrolimus, sirolimus, everolimus, cyclosporine, and ascomycin, or mycophenolic acid. The solution may be non-invasively or topically administered as drops, ointments, gels, creams, etc. and may include eye lubricants and contact lens solutions. The solution may contain a supratherapeutic concentration of agent(s) so that a therapeutic concentration of a topically administered solution accumulates in a diseased ocular structure sufficient to treat the disease. The agent(s) may be formulated with polymers or other components for extended or slow release to provide a substantially constant concentration over the course of treatment.

**BEST AVAILABLE COPY**

-1-

OCULAR SOLUTIONS CONTAINING A MACROLIDE ANTIBIOTIC AND/OR MYCOPHENOLIC ACID

This application is a Continuation-in-Part of U.S. Patent application Serial No. 10/667,161 filed September 19, 2003, which is expressly incorporated by reference herein in its entirety.

Field of the Invention

The invention is directed to ocular solutions containing macrolide antibiotics to provide anti-inflammatory and other beneficial effects.

Background

5 The eye is naturally bathed internally and externally by ocular fluids. The external portion of the eye is lubricated by lacrimal fluids (tears). The internal portion of the eye has two fluid-containing chambers: the anterior chamber contains the aqueous humor or aqueous, and the posterior chamber contain the vitreous humor or vitreous.

10 Various conditions require the need to introduce fluids into or on the surface of the eye to replace or replenish naturally occurring fluids. The loss of naturally occurring ocular fluids may be due to normal aging, pathological conditions, surgical intervention, etc. For example, during ocular surgery, the vitreous is frequently removed and must thereafter be replaced. Commercially available irrigating solutions are often used to replace some or all of the vitreous, such as irrigating solutions infused to replace the vitreous removed during vitrectomy 15 and thereby to maintain the shape of the globe. The composition and other properties of these solutions may affect the surgical outcome for the patient, for example, a solution may affect the

clarity of the cornea and lens, which may result in decreased visual acuity. Additionally, swelling of the cornea during vitrectomy may be influenced by components of the irrigating solution. Other conditions such as dry eye disease result in decreased external lubrication, and topical solutions such as eye drops are often used to provide relief. Wash solutions are used topically to remove foreign material from the external surface of the eye and invasively to clear the cornea and other structures during surgery.

Ocular solutions, for introduction into the eye and/or topical application, with improved properties are desirable. The invention describes such compositions and method of using the compositions.

#### SUMMARY OF THE INVENTION

A substitute for an intraocular irrigating, wash, or volume replacement solution is disclosed. The solution contains a concentration in the range from about 1 ng/ml to about 200  $\mu$ g/ml of a macrolide antibiotic and/or mycophenolic acid. This provides beneficial properties, such as reducing inflammation at a surgical site (anti-inflammatory effect), inhibiting cell migration and cell proliferation (anti-proliferative and anti-migratory effects), inhibiting the growth of new blood vessels at the site of an ocular tumor (anti-angiogenic effect), reducing the growth of bacteria, fungi, etc. (anti-microbial and anti-fungal effects). Its anti-inflammatory effect desirably occurs without an increase in intraocular pressure, which may occur when steroids are administered to control ocular inflammation. Such a composition may be used in patients undergoing ocular surgery such as cataract surgery, retinal repair, etc.

The macrolide and/or mycophenolic acid can be added to a commercially available ocular solution, or can be formulated with an ocular solution. The macrolide antibiotic can be tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide. It can be formulated in an inert matrix, a capsule, a liposome, etc. It can be inserted, injected, or implanted within a specific site of the eye (e.g., within the lens capsule), or applied generally to clear or wash a surgical field.

In one embodiment, the inventive ocular composition is administered to a patient undergoing cataract surgery. The solution, containing a concentration in the range from about

20  $\mu\text{g}/\text{ml}$  to about 200  $\mu\text{g}/\text{ml}$  (about 0.002%<sup>w/w</sup> to about 0.02%<sup>w/w</sup>) of a macrolide antibiotic and/or mycophenolic acid is introduced within the capsule of the lens after the diseased lens has been removed and before the replacement lens is inserted. Microspheres or microcapsules of the macrolide antibiotic and/or mycophenolic acid can be implanted within the capsule in an alternate embodiment. This can be used to reduce opacification of the posterior capsule, which is a common problem following cataract surgery.

An implantable lens which retains at least one of a macrolide antibiotic or mycophenolic acid is also disclosed. This system provides a replacement lens ready for surgical implantation in a patient undergoing cataract surgery, with the lens containing a concentration of a macrolide antibiotic and/or mycophenolic acid. When the lens is implanted within the lens capsule of a patient's eye, the antibiotic or mycophenolic acid is then released to provide therapeutic effects to the capsule (e.g., anti-cell proliferative effects, anti-inflammatory effects, etc).

In another embodiment, an ocular solution containing a supratherapeutic concentration of a macrolide antibiotic and/or mycophenolic acid is administered topically. The topically administered compounds accumulate within an ocular structure, such as the choroid, retina, or uvea, to a concentration effective to treat ocular pathologies affecting those structures. Such pathologies include diabetic retinopathy, retinitis pigmentosa, age related macular degeneration, scleritis, uveitis, vasculitis, retinoblastoma, choroidal melanoma, pre-malignant and malignant melanoma of the conjunctiva.

In another embodiment, a supratherapeutic concentration of a macrolide antibiotic and/or mycophenolic acid is administered on a contact lens or intraocular device with the agent(s) in an extended release formulation. The agent(s) is formulated to release a maximum intraocular concentration up to about 40  $\mu\text{g}/\text{ml}$ .

These and other advantages of the invention will be apparent in light of the following figures and detailed description.

#### **DETAILED DESCRIPTION**

An ocular solution containing one or more macrolide antibiotics and/or mycophenolic acid is disclosed. The ocular solution may be any physiologically compatible

ocular solution. It may be used externally (e.g. topical administration such as on the surface of the conjunctiva) or internally (e.g. invasive administration.)

Ocular solutions are frequently administered to a patient following ocular surgery; macrolide antibiotics in these solutions desirably provide anti-inflammatory effects which aid in post-surgical recovery. In addition, macrolide antibiotics provide these anti-inflammatory effects without an increase in intraocular pressure that often accompanies administration of steroids to post-surgical patients to control inflammation.

Macrolide antibiotics also reduce cell proliferation and cell migration. This may promote the healing process, and may also provide an anti-angiogenesis effect to retard the proliferation and/or growth of new vessels. As one example, controlling the growth of new blood vessels is a way to control proliferation of tumor cells; macrolide antibiotics in an ocular solution may be helpful in controlling ocular neoplasms or tumors. As another example, the solutions may be used in patients having diseases characterized by abnormal angiogenesis, such as certain types of cancers, diabetic retinopathy, and sickle cell retinopathy, in which an anti-angiogenesis effect is desirable. Macrolide antibiotics also provide antimicrobial and antifungal properties to ocular solutions.

Macrolide antibiotics and/or mycophenolic acid may be used to enhance therapy in ocular diseases. Such enhancement is generally defined as treatment of these diseases. Treatment is not limited to total elimination of disease, but is broadly defined to include any enhancement or improvement toward the result of diminishing or alleviating the disease symptoms, onset, course, duration, severity, etc. The inventive use of macrolide antibiotics and/or mycophenolic acid may be combined with other agents, such as chemotherapeutic agents for treatment of ocular malignancies, and cyclooxygenase inhibitors for reducing inflammation. Both acute and chronic ocular diseases are treated by the inventive method and composition, and include retinitis pigmentosa, diabetic retinopathy, age related macular degeneration, scleritis, uveitis, and vasculitis. Ocular cancers such as retinoblastoma, choroidal melanoma, pre-malignant and malignant conjunctival melanoma are also treated by the invention.

It will be appreciated that the inventive composition need not be in the physical form of a true solution, but instead may be a suspension, an emulsion, a gel, etc. It may also encompass the macrolide antibiotic and/or mycophenolic acid in the form of polymeric

compositions, microspheres, microvesicles, microcapsules, and/or liposomes. In addition, ocular solutions for topical application may take the form of any of the above, as well as an ointment, a cream, a lotion, etc. Thus, the term solution is used for convenience but encompasses other physical states. It will also be appreciated that the macrolide antibiotics may be included in the formulation for preparing an ocular solution, or may be added in dry form or in concentrated form to an already prepared ocular solution.

The ocular solution may be one that is used as an ocular irrigating solution and/or as a volume replacement solution during ocular surgery. It is thus a substitute for an ocular fluid, such as the vitreous, and/or a substitute for a commercially available irrigating solution that may be used during ocular surgery. It may also be one that is used topically, and thus encompasses eye drops, eye wash solutions, and contact lens solutions. It may be used in over the counter (OTC) ocular solutions for topical application, for example, in ocular solutions such as artificial tears or lubricants. One commercially available ophthalmic lubricant is Viva-Drops®, available from Vision Pharmaceuticals, Inc. (Mitchell SD). The invention includes but is not limited to this particular embodiment.

In one embodiment, an ocular solution contains at least one macrolide antibiotic and/or mycophenolic acid and is used for intraocular administration. Intraocular administration indicates an invasive route of administration, compared to a topical route of administration. In this embodiment, the ocular solution containing the macrolide antibiotic(s) may be an irrigating solution, a volume replacement solution, and/or a wash solution.

In another embodiment, an ocular solution containing a macrolide antibiotic and/or mycophenolic acid is administered topically, for example, on the conjunctiva or the mucosal surface of the lid, to treat diseases in other areas of the eye, such as the choroid, retina, and uvea. Administration of such compounds was previously restricted to systemic or invasive routes, because it was thought that the higher concentrations of these compounds in internal ocular structures required for efficacy could not be achieved by topical administration. However, an efficacious therapeutic concentration of a topically-administered macrolide antibiotic and/or mycophenolic acid in an ocular structure may be achieved by topically administering a supratherapeutic concentration for a duration such that a therapeutic concentration is attained in the diseased structure.

While not bound by any theory, one reason this therapeutic concentration may be achieved with topical administration is that the structural affinity of the antibiotic and/or mycophenolic acid for lipids results in their accumulation in lipophilic regions of the choroid, retina, etc. Unexpectedly, such topically administered compositions can thus be used to treat pathologies that affect these structures without invasive methods, such as intraocular injection or systemic administration. Examples of pathologies include, but are not limited to, retinopathy including diabetic retinopathy, retinitis pigmentosa, age related macular degeneration, scleritis, uveitis, vasculitis, and oncological diseases affecting the eye such as retinoblastoma, choroidal melanoma, pre-malignant and malignant conjunctival melanoma. Retinoblastoma is a malignant tumor of the retina, typically affecting children under the age of six. Choroidal melanoma is a malignant tumor of the pigmented cells of the choroid. Melanoma of the conjunctiva may be classified as primary acquired melanosis (PAM) with or without atypia, or conjunctival melanoma. For cancers of the eye, treatment with a macrolide antibiotic/mycophenolic acid may provide an anti-angiogenic effect and thereby desirably diminish the blood supply to the tumor. Such treatment may augment or enhance the effects of specific radiation treatments and/or chemotherapeutic agents. For example, the macrolide antibiotic and/or mycophenolic acid may be added in polymer form, providing extended release, to carboplatin, cisplatin, methotrexate, etc., in topical chemotherapy eye drops. Diseases such as diabetic retinopathy, retinitis pigmentosa, and age related macular degeneration are typically chronic so that treatment is prolonged, while diseases such as scleritis, uveitis and vasculitis may be acute with treatment occurring for a shorter duration, that is, over the course of the disease. The invention encompasses both types of treatment, as will subsequently be described.

The topically administered composition must cross ocular structures such as the conjunctiva and sclera to reach structures such as the choroid, retina, and uvea. In transit of the composition, a natural gradient of the active agent(s) may form within the eye. A structure such as the sclera may act as a depot or repository for the active agent(s), providing extended release. Thus, topical administration may provide results similar to a slow release formulation, as will be described. Such formulations desirably decrease the frequency of administration or dosing. For example, patients being treated with the inventive method already have decreased visual acuity, and topical ocular administration of drugs may be difficult and/or uncomfortable for

them. Reducing the frequency of administration enhances compliance, while providing a therapeutic dosage of the composition.

In one embodiment, a concentration of macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topically administered solution may range from about 0.5% <sup>w/v</sup> to about 10% <sup>w/v</sup>. In another embodiment, a concentration of macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topically administered solution may range from about 3% <sup>w/v</sup> to about 5% <sup>w/v</sup>. In another embodiment, a concentration of macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topically administered solution may range from about 1% <sup>w/v</sup> to about 3% <sup>w/v</sup>. In another embodiment, a concentration of macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topically administered solution may range from about 3% <sup>w/v</sup> to about 10% <sup>w/v</sup>. In another embodiment, a concentration of macrolide antibiotic and/or mycophenolic acid may range from about 0.1% to about 10% in a topical ocular formulation for treating diabetic retinopathy, age related macular degeneration, or retinitis pigmentosa. In another embodiment, concentrations of macrolide antibiotic and/or mycophenolic acid up to about 2%, up to about 5%, up to about 10%, or exceeding 10% are formulated for topical administration when the compound(s) is bound to a matrix or polymer which slowly releases the compound(s) over time while not exceeding an intraocular concentration of 40 µg/ml, as is subsequently described. In any of the above embodiments, the patient is typically instructed to periodically administer the solution, from once per day up to several times per day, over the course of the disease. In one embodiment, the composition may be administered daily at bedtime. It will be appreciated that some patients with a chronic disease will require continued treatment over many years.

The inventive composition may be used in physiologic ophthalmic irrigating solutions. One example is Balanced Salt Solution (BSS<sup>®</sup>, available from Alcon Laboratories, Randburg, South Africa), containing per ml 0.64% sodium chloride, 0.075% potassium chloride, 0.048% calcium chloride, 0.03% magnesium chloride, 0.39% sodium acetate, and 0.17% sodium citrate dihydrate, as well as sodium hydroxide and/or hydrochloric acid to adjust pH, and water for injection. Another example is Ocular Irrigation Solution<sup>®</sup> (Allergan, Irvine CA). Another example is lactated Ringer's solution. Another example is a normal saline solution. Another example is normal saline adjusted to pH 7.4 with sodium bicarbonate.

The inventive composition may also be used in ophthalmic volume replacement solutions. For example, it may be introduced into the posterior chamber of the eye to replace the vitreous that is removed during the repair of retinal disorders (vitrectomy).

The inventive composition may also be introduced into the lens capsule during cataract surgery. A cloudy and discolored lens, referred to as a cataract, causes decreased vision and treatment requires that the lens be surgically removed. Cataract surgery usually involves phacoemulsification of the diseased lens inside the capsule, aspiration of the emulsified material, irrigation, and insertion of a replacement intraocular lens (IOL) within the capsule.

Following cataract surgery, there is frequently opacification of the posterior capsule which also diminishes visual acuity. Surgical techniques to minimize posterior capsule opacification have variable success, and patients undergoing cataract surgery may require an additional procedure to attend to the capsular opacification that subsequently occurs.

A complication for IOL implantation is post-operative opacification. This occurs as a result of lens epithelial cells (LEC) which migrate around the posterior capsule, and may be due to lack of maximum contact between the IOL optic and the posterior capsule. In children treated for pediatric cataracts, leaving the posterior capsule intact after IOL implantation predisposes them to secondary cataract formation and severe visual axis opacification (VAO). This usually requires surgery to prevent VAO and an anterior vitrectomy to maintain a clear visual axis during pediatric IOL surgery. Thus, reduction in the extent of cell migration and/or cell proliferation following cataract surgery is desirable.

In this embodiment of the invention, an irrigating or volume replacement solution containing at least one macrolide antibiotic and/or mycophenolic acid is administered to the capsule with or before inserting the replacement lens. Without being bound by any theory, the macrolide antibiotic and/or mycophenolic acid may reduce posterior capsular opacification and visual axis opacification by its inhibitory effect on ocular cell proliferation and cell migration.

The macrolide antibiotic and/or mycophenolic acid can also be provided on a device, such as a contact lens applied to the exterior surface of an eye, or a lens that will be implanted within a patient's eye. Implantable lenses include any IOL used to replace a patient's diseased lens following cataract surgery, including but not limited to those manufactured by

Bausch and Lomb (Rochester NY), Alcon (Fort Worth TX), Allergan (Irvine CA), and Advanced Medical Optics (Santa Ana CA). The system provides a therapeutic replacement lens ready for surgical implantation in a patient. When the lens is implanted within the lens capsule, the antibiotic and/or mycophenolic acid provides therapeutic effects (e.g., anti-cell proliferative effects, anti-inflammatory effects, etc) to the eye.

A concentration of the macrolide antibiotic and/or mycophenolic acid within the capsule is provided to achieve the previously described therapeutic effect. In one embodiment, the concentration ranges from about 20  $\mu\text{g}/\text{ml}$  (about 0.002%<sup>w/v</sup>) to about 2000  $\mu\text{g}/\text{ml}$  (about 0.2%<sup>w/v</sup>). In another embodiment, the concentration ranges from about 200  $\mu\text{g}/\text{ml}$  (about 0.02%<sup>w/v</sup>) to about 2000  $\mu\text{g}/\text{ml}$  (about 0.2%<sup>w/v</sup>). In another embodiment, the concentration ranges from about 20  $\mu\text{g}/\text{ml}$  (about 0.002%<sup>w/v</sup>) to about 200  $\mu\text{g}/\text{ml}$  (about 0.02%<sup>w/v</sup>).

In another embodiment, the IOL or device contains a concentration of the macrolide antibiotic and/or mycophenolic acid up to about 2%<sup>w/v</sup> formulated so that the concentration in the eye at any time does not exceed about 40  $\mu\text{g}/\text{ml}$ . For example, the intraocular concentration of the active agent(s) at any time may be in the range of about 10  $\mu\text{g}/\text{ml}$  to about 30  $\mu\text{g}/\text{ml}$ . Such formulation methods are known to one skilled in the art and include, but are not limited to, extended release formulations subsequently described.

The contact lens or IOL may be made of hydrophobic or hydrophilic material. The type of material determines whether the lens cannot fold, is rigid and requires a large incision to insert, or is flexible to allow the lens to be rolled, compressed, or folded for insertion through a smaller incision. The most common materials used in lenses are various chemical modifications of silicon, hydrophobic acrylates, hydrophobic acrylates, and hydrogels which contain water to impart gel-like characteristic to the material. Each of these can be formulated or treated to contain a solution containing a macrolide antibiotic and/or mycophenolic acid.

In one embodiment, the contact lens or implantable IOL is packaged in an ophthalmically acceptable medium which contains the macrolide antibiotic and/or mycophenolic acid. For example, a porous hydrogel lens (e.g., Hydroview®, Bausch & Lomb Surgical, Rochester NY) retains the macrolide antibiotic and/or mycophenolic acid within the pores. Upon application of the contact lens or insertion/implantation of the lens into the lens capsule, the

10

macrolide antibiotic and/or mycophenolic acid is released. An ocular device containing agent(s) in a slow-release system provides extended therapy, for example, over a post-surgical recovery period as the actives are slowly released through the porous elements. It may also be the administration method of choice in some patients, such as patients who are elderly, who cannot reliably self-administer topical ocular medications, who must receive chronic therapy, etc.

In another embodiment, a contact lens or implantable lens is coated to provide the macrolide antibiotic and/or mycophenolic acid. This embodiment may be used with a non-hydrogel hydrophilic lens, a hydrophobic lens, a lens made from an acrylic material (e.g., AcrySof®; Alcon, Fort Worth TX; Sensar®; Advanced Medical Optics, Santa Ana CA), a silicone lens (e.g., CeeOn®, Pharmacia & Upjohn Company, Pickering OH), etc. Coating and/or incorporation procedures that may be used are known to one skilled in the art; for example, as disclosed in U.S. Patent Nos. 6,238,799; 6,179,817; 6,306,422; and 6,258,856, each of which is incorporated by reference herein in its entirety. The macrolide antibiotic and/or mycophenolic acid may be added to the storage solution during packaging of the lens, or may be incorporated into the manufacture of the lens. For example, the macrolide antibiotic and/or mycophenolic acid may be incorporated into either or both the hydration fluid in the formation of a hydrophilic or hydrogel lens, or in the storage solution. In another example, the macrolide antibiotic and/or mycophenolic acid may be in an acceptable encapsulated form in a hydrogel IOL for extended long term release.

The inventive composition may also be used as an ocular wash solution, for example, to clear the surgical field during intraocular surgery.

In each of the above embodiments, any macrolide antibiotic alone or in combination may be used. Embodiments of the invention include various ocular-compatible concentrations of the macrolide antibiotic(s) and/or mycophenolic acid sufficient to provide an anti-inflammatory, anti-proliferative, anti-cell migration, anti-fungal, etc. effect. Concentrations may depend upon the use for the composition, as is known to one skilled in the art. Thus, in these embodiments, the invention is not limited to a specific concentration of macrolide antibiotic and/or mycophenolic acid. In general, the macrolide antibiotic and/or mycophenolic acid is present in the ocular solution at concentrations ranging from about 1 ng/ml (about 0.0000001%<sup>w/v</sup>) to about 200 µg/ml (about 0.02%<sup>w/v</sup>). In one embodiment, the macrolide

antibiotic and/or mycophenolic acid is present in the ocular solution at a concentration of about 1  $\mu\text{g}/\text{ml}$  (about 0.0001%<sup>w/v</sup>). For use to reduce capsular opacification following cataract surgery, concentrations ranging from about 1  $\mu\text{g}/\text{ml}$  (about 0.0001%<sup>w/v</sup>) to about 200  $\mu\text{g}/\text{ml}$  (about 0.02%<sup>w/v</sup>), or from about 20  $\mu\text{g}/\text{ml}$  (about 0.002%<sup>w/v</sup>) to about 200  $\mu\text{g}/\text{ml}$  (about 0.02%<sup>w/v</sup>), may be used. The properties of the macrolide- and/or mycophenolic acid-containing ocular solution are compatible with ocular tissues.

The macrolide antibiotic and/or mycophenolic acid may be formulated with a viscoelastic substance such as hyaluronic acid, or may be contained in microspheres, macrospheres, microvesicles, macrovesicles, microcapsules, macrocapsules, liposomes, etc., as described in co-pending U.S. Patent application Serial No. 10/631,143 which is expressly incorporated by reference herein in its entirety. This embodiment may be used with solutions administered to prevent capsular opacification following cataract surgery, as previously described.

Liposomes may be prepared from dipalmitoyl phosphatidylcholine (DPPC), for example, from egg phosphatidylcholine (PC), a lipid with a low heat of transition. Liposomes are made using standard procedures as known to one skilled in the art. The macrolide antibiotic(s), in amounts ranging from nanogram to microgram quantities, or higher, is added to a solution of egg PC, and the lipophilic drug binds to the liposome.

A time-release drug delivery system may be administered intraocularly to result in sustained release of the macrolide antibiotic(s) over a period of time. The formulation may be in the form of a vehicle, such as a micro- or macro-capsule or matrix of biocompatible polymers such as polycaprolactone, polyglycolic acid, polylactic acid, polyanhydrides, polylactide-co-glycolides, polyamino acids, polyethylene oxide, acrylic terminated polyethylene oxide, polyamides, polyethylenes, polyacrylonitriles, polyphosphazenes, poly(ortho esters), sucrose acetate isobutyrate (SAIB), and other polymers such as those disclosed in U.S. Patent Nos. 6,667,371; 6,613,355; 6,596,296; 6,413,536; 5,968,543; 4,079,038; 4,093,709; 4,131,648; 4,138,344; 4,180,646; 4,304,767; 4,946,931, each of which is expressly incorporated by reference herein in its entirety, or lipids that may be formulated as microspheres or liposomes. A microscopic or macroscopic formulation may be administered through a needle, or may be implanted by suturing within the eye, for example, within the lens capsule. As an illustrative

example, sirolimus may be mixed with polyvinyl alcohol (PVA), the mixture then dried and coated with ethylene vinyl acetate, then cooled again with PVA. In a formulation for intraocular administration, the liposome capsule degrades due to cellular digestion providing a slow release drug delivery system, allowing the patient a constant exposure to the drug over time.

A time-release microscopic or macroscopic formulation may also be topically administered. The sustained-release antibiotic(s) and/or mycophenolic acid accumulates at concentrations in ocular structures such as the choroid or retina sufficient to effect treatment and diseases affecting these structures.

Delayed or extended release properties may be provided through various formulations of the vehicle (coated or uncoated microsphere, coated or uncoated capsule, lipid or polymer components, unilamellar or multilamellar structure, and combinations of the above, etc.). Other variables may include the patient's pharmacokinetic-pharmacodynamic parameters (e.g., body mass, gender, plasma clearance rate, hepatic function, etc.). The formulation and loading of microspheres, microcapsules, liposomes, etc. and their ocular implantation are standard techniques known by one skilled in the art, for example, the use a ganciclovir sustained-release implant to treat cytomegalovirus retinitis, disclosed in Vitreoretinal Surgical Techniques, Peyman et al., Eds. (Martin Dunitz, London 2001, chapter 45); Handbook of Pharmaceutical Controlled Release Technology, Wise, Ed. (Marcel Dekker, New York 2000), the relevant sections of which are incorporated by reference herein in their entirety.

Examples of macrolide antibiotics that may be used for intraocular administration include, but are not limited to, tacrolimus, Cyclosporin A, sirolimus, aztreonam, and everolimus. Tacrolimus (Prograf<sup>®</sup>, Fujisawa Healthcare, Deerfield, IL; FK-506), a macrolide immunosuppressant produced by *Streptomyces tsukubaensis*, is a tricyclic hydrophobic compound that is practically insoluble in water, but is freely soluble in ethanol and is very soluble in methanol and chloroform. It is available under prescription as either capsules for oral administration or as a sterile solution for intravenous administration. The solution contains the equivalent of 5 mg anhydrous tacrolimus in 1 ml of polyoxyl 60 hydrogenated castor oil (HCO-60), 200 mg, and dehydrated alcohol (USP, 80.0%<sup>vw</sup>), and must be diluted with a solution of 0.9% NaCl or 5% dextrose before use.

Tacrolimus has been used for topical administration to treat a variety of dermatoses. Topical administration of tacrolimus at doses ranging from 0.03%-0.3% resulted in significant clinical improvement in atopic dermatitis after 2-3 weeks treatment, and tacrolimus treatment of other dermatologic diseases shows promise. Tacrolimus, like cyclosporine, blocks the signal transduction pathway needed to induce interleukin-2 gene expression and thereby activate T lymphocytes. In addition to suppressing T cell activation, tacrolimus inhibits anti-IgE-triggered histamine release and inhibits prostaglandin D2 synthesis in human skin mast cells. While oral administration produces limiting adverse effects (systemic immunosuppression, infection, neural toxicity, nephrotoxicity, and hypertension), topical administration for treatment of dermatoses at concentrations up to 0.3% showed no significant difference in effects between treated and control groups. In addition, tacrolimus is well tolerated locally and only occasionally causes mild irritation.

The use of tacrolimus as a specific medicament for treatment of ocular disease has been disclosed in U.S. Patent No. 6,489,335 and co-pending U.S. Patent application Serial No. 10/247,220, each of which is expressly incorporated by reference herein in its entirety. For example, tacrolimus may be contained in an aqueous-based cream excipient for topical application, or it may be injected intraocularly, or it may be administered surgically as an ocular implant.

None of these publications disclose the topical ocular administration of supratherapeutic concentrations of a macrolide antibiotic and/or mycophenolic acid, either alone or with other agents such as chemotherapeutic agents and/or inhibitors of cyclooxygenase, at the disclosed doses and formulations for treating ocular pathologies such as diabetic retinopathy, retinitis pigmentosa, age related macular degeneration, uveitis, vasculitis, retinoblastoma, choroidal melanoma, pre-malignant and malignant melanoma of the conjunctiva, as in the inventive method.

Cyclosporin A (cyclosporine, topical formulation Arrestase<sup>®</sup>, Allergan Inc.) is a cyclic peptide produced by *Trichoderma polysporum*. It is available commercially, for example, from Sigma-Aldrich (St. Louis MO). It is an immunosuppressant and acts in a particular subset of T lymphocytes, the helper T cells. Cyclosporin A exerts an immunosuppressant effect by inhibiting production of the cytokine interleukin 2. Each of Cyclosporin A and tacrolimus, another

immunosuppressant, produces significant renal and hepatic toxicity when each is administered systemically; because of this toxicity, they are not administered together.

Cyclosporin A has been administered to treat ocular conditions such as glaucoma, corticosteroid-induced ocular hypertension, allograft rejection, infections, and ocular surface disease. Its use has been reported for the treatment of uveitis (inflammation of the uvea) by topical, intravitreal or systemic administration with doses of 0.05%, 0.1%, and 0.5%.

Cyclosporin A has good penetration into the cornea but not into the anterior chamber, and does not increase intraocular pressure or cause cataracts. Its known toxicity had previously limited its use for other ocular diseases.

The use of Cyclosporin A as a specific medicament for treatment of ocular disease with reduced toxicity has been described in co-pending U.S. Patent application Serial No. 10/289,772, which is expressly incorporated by reference herein in its entirety.

Sirolimus, also known as rapamycin, RAPA, and Rapamune<sup>®</sup>, is a triene macrolide antibiotic derived from *Streptomyces hygroscopicus* and originally developed as an antifungal agent. Subsequently, it has shown anti-inflammatory, anti-tumor, and immunosuppressive properties. Ascomycin, also known as pimecrolimus, Immunomycin, and FR-900520, is an ethyl analog of tacrolimus and has strong immunosuppressant properties. It inhibits Th1 and Th2 cytokines, and preferentially inhibits activation of mast cells, and is used to treat contact dermatitis and other dermatological conditions. Sirolimus and ascomycin are commercially available, e.g., A.G. Scientific, Inc. (San Diego, CA).

Regarding its immunosuppressive potential, sirolimus has some synergistic effect with Cyclosporin A. It has been reported that sirolimus has a different mode of action compared to Cyclosporin A and tacrolimus. All three agents are immunosuppressants which affect the action of immune cell modulators (cytokines), but do not affect the immune cells themselves. However, while all three agents affect immune cell modulators, they do so differently: Cyclosporin A and tacrolimus prevent synthesis of cytokine messengers, specifically interleukin-2, while sirolimus acts on cytokine that has already been synthesized, preventing it from reaching immune cells.

Sirolimus inhibits inflammation by acting on both T-lymphocytes and dendritic cells. The latter are the first cells to recognize antigens. Sirolimus blocks the growth of dendritic

15

cells and a number of other cells, such as tumors and endothelial cells, which are activated by the tumor cell releasing vascular endothelial growth factor (VEGF). VEGF is a central regulator of angiogenesis (formation of new blood vessels from pre-existing vessels) and vasculogenesis (development of embryonic vasculature through an influence on endothelial cell differentiation and organization). Diseases that are characterized by abnormal angiogenesis and vasculogenesis, such as some cancers and some ocular diseases, may show abnormal production of VEGF. Thus, control of VEGF function may be one means to control or treat these diseases. Sirolimus has also been used in the prevention of smooth muscle hyperplasia after coronary stent surgery. The use of sirolimus and ascomycin as specific medicaments for treatment of ocular disease has been disclosed in co-pending U.S. Patent application Serial No. 10/631,143, which is expressly incorporated by reference herein in its entirety.

Everolimus, also known as RAD-001, SCZ RAD, Certican™ (Novartis, Basel Switzerland), is an analog of sirolimus but is a new and distinct chemical entity. It is an oral immunosuppressant that inhibits growth factor-induced cell proliferation and thus reduces acute organ rejection and vasculopathy, the proliferation of smooth muscle cells in the innermost wall of grafts that restricts blood supply.

Mycophenolic acid (MPA) is the active compound formed following the administration of mycophenolate mofetil (MMF). The prodrug is the morpholinoethyl ester of mycophenolic acid. Mycophenolic acid is an antileukemic and immunosuppressant agent used in patients undergoing chemotherapy for cancer and in transplant recipients.

The topical ocular administration of these agents, either alone, in combination, or with chemotherapeutic agents or cyclooxygenase inhibitors, at the disclosed concentrations and formulations to treat ocular pathologies such as diabetic retinopathy, retinitis pigmentosa, age related macular degeneration, uveitis, vasculitis, retinoblastoma, choroidal melanoma, pre-malignant and malignant conjunctival melanoma has not been reported.

The addition of these agents, either alone or in combination, to invasively administered ocular solutions according to the invention provides beneficial anti-inflammatory, anti-proliferative, anti-cell migration, anti-angiogenic, antimicrobial, and antifungal properties.

It will be appreciated that the invention encompasses the use of macrolide antibiotics and/or mycophenolic acid, in addition to those previously described, in an ocular

solution. These include, for example, the known antibiotics erythromycin and its derivatives such as azithromycin and clarithromycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, troleandomycin, tylosin, and roxithromycin. The invention also includes new macrolide antibiotic scaffolds and derivatives in development, including but not limited to the ketolides ABT-773 and telithromycin as described by Schonfeld and Kirst (Eds.) in *Macrolide Antibiotics*, Birkhauser, Basel Switzerland (2002); macrolides derived from leucomycins, as described in U.S. Patent Nos. 6,436,906; 6,440,942; and 6,462,026 assigned to Enanta Pharmaceuticals (Watertown MA); and lincosamides.

In addition to the above described uses, the invention comprises ocular solutions for topical (non-invasive) ocular administration with everolimus, erythromycin, azithromycin, clarithromycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, and mycophenolic acid, as well as the previously described new macrolide antibiotic scaffolds and derivatives in development, including but not limited to the ketolides ABT-773 and telithromycin, macrolides derived from leucomycins, and lincosamides.

The macrolide antibiotics are included with ocular solutions for any use. They may be included with topical ocular solutions containing chemotherapeutic agents for treating ocular malignancies or pre-malignant conditions. They may be included with topical ocular solutions containing inhibitors of cyclooxygenase for reducing ocular inflammation. In one embodiment, age related macular degeneration is treated by administering a topical ocular formulation containing at least one macrolide antibiotic and/or mycophenolic acid and at least one cyclooxygenase inhibitor. The cyclooxygenase inhibitor(s) may be present in a concentration of 0.5% to 20% of the composition. Inhibitors of cyclooxygenase (COX inhibitors) are well known (e.g., Vioxx®, Celebrex®) and include, but are not limited to, ibuprofen, indomethacin, piroxicam, and tranylcypromine HCl. The macrolide antibiotic may be added together or separately as individual components in the preparation of an ocular solution. Alternatively, a solution of the macrolide antibiotic may be prepared and then added to the ocular solution. The solutions may be commercial irrigating solutions that contain other known components, such as various anions and cations, buffers to regulate pH, adenosine, calcium, glucose, bicarbonate, dextrose, dextran 40 (a low molecular weight colloidal osmotic agent), gentamicin, dexamethasone, selenium, zinc, and gluconide. The macrolide antibiotic may be added to commercial ocular lubricating

solutions, such as artificial tears. The macrolide antibiotic may be included with commercial ocular wash solutions. The macrolide antibiotic may be included with contact lens wash, rinse, and wetting solutions. Any solution for ocular administration, either administration to the exterior surface of the eye or to one of the interior chambers of the eye, may contain the macrolide antibiotic.

The invention is also not limited to human use, and encompasses the use of ocular solutions containing at least one macrolide antibiotic for veterinary use. For example, lincosamides have been used in animals; an ocular solution containing a lincosamide may be used as a veterinary irrigation solution, volume replacement solution, topical wash or lubricant solution, etc.

The invention provides general purpose ocular solutions in the form of eye drops, eye washes, eye irrigating solutions, volume replacement solutions, contact lens solutions, etc. that contain one or more of the above macrolide antibiotics. In various embodiments, the ocular solution may be in single or multi-dose containers (e.g., 10 ml, 20 ml, 30 ml, 500 ml).

Other variations or embodiments of the invention will also be apparent to one of ordinary skill in the art from the above figures and descriptions. Thus, the foregoing embodiments are not to be construed as limiting the scope of this invention.

What is claimed is:

1. A composition comprising a solution for intraocular administration containing a concentration in the range between about 1 ng/ml to about 200  $\mu$ g/ml of at least one of a macrolide antibiotic or mycophenolic acid as a substitute for an ocular or operative fluid.
2. The composition of claim 1 wherein the macrolide antibiotic is at a concentration of about 1  $\mu$ g/ml.
3. The composition of claim 1 wherein the macrolide antibiotic is at a concentration in the range of about 1  $\mu$ g/ml to about 20  $\mu$ g/ml.
4. The composition of claim 1 wherein the macrolide antibiotic is at a concentration in the range of about 20  $\mu$ g/ml to about 200  $\mu$ g/ml.
5. The composition of claim 1 wherein the solution is selected from at least one of an irrigation solution, a volume replacement solution, and a wash solution.
6. The composition of claim 1 wherein the macrolide antibiotic is at least one of tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide.
7. The composition of claim 1 wherein the macrolide antibiotic or mycophenolic acid is formulated as at least one of a microcapsule, a microsphere, a microvesicle, and a liposome.
8. The composition of claim 1 wherein the macrolide antibiotic or mycophenolic acid is provided to a prepared ocular solution.
9. The composition of claim 1 wherein the macrolide antibiotic or mycophenolic acid is provided in formulating an ocular solution.

10. A therapeutic method comprising providing to an eye of a patient an ocular solution containing at least one of a macrolide antibiotic or mycophenolic acid at a concentration in the range between about 1 ng/ml to about 200  $\mu$ g/ml to provide a therapeutic effect.

11. The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid provides at least one of an anti-inflammatory effect, an anti-cell proliferation effect, an anti-cell migration effect, an anti-angiogenesis effect, an antimicrobial effect, and an antifungal effect.

12. The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid provides an anti-inflammatory effect without increased intraocular pressure.

13. The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid provides an anti-angiogenic effect in a patient with an ocular tumor, a patient with diabetes, or a patient with sickle cell anemia.

14. The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid is at a concentration of about 1  $\mu$ g/ml.

15. The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid is at a concentration ranging from about 1 ng/ml to about 20  $\mu$ g/ml.

16. The method of claim 10 wherein the macrolide antibiotic or mycophenolic acid is at a concentration ranging from about 20  $\mu$ g/ml to about 200  $\mu$ g/ml.

17. A therapeutic method comprising intraocularly administering to a patient undergoing cataract surgery an ocular solution containing at least one of a macrolide antibiotic or mycophenolic acid at a concentration in the range from about 20  $\mu$ g/ml to about 200  $\mu$ g/ml within a lens capsule prior to insertion of a replacement intraocular lens.

20

18. The method of claim 17 wherein the solution reduces opacification of the posterior capsule.

19. The method of claim 17 wherein the macrolide antibiotic is formulated as at least one of a liposome, a macrosphere, a microsphere, a macrocapsule, a microcapsule, a macrovesicle, and a microvesicle.

20. The method of claim 17 wherein the macrolide antibiotic or mycophenolic acid is at a concentration in the range of about 20  $\mu\text{g}/\text{ml}$  to about 200  $\mu\text{g}/\text{ml}$ .

21. The method of claim 19 wherein the macrolide antibiotic or mycophenolic acid is implanted within the capsule.

22. An article comprising an implantable ocular replacement lens in a solution containing a concentration of a macrolide antibiotic or mycophenolic acid sufficient to provide the lens with at least one effect selected from anti-cell proliferation, anti-cell migration, anti-inflammatory, anti-angiogenesis, antimicrobial, and antifungal.

23. An article comprising an implantable ocular replacement lens containing at least one macrolide antibiotic or mycophenolic acid.

24. The article of claim 23 wherein the antibiotic or mycophenolic acid is in a solution in which the lens is contained.

25. The article of claim 23 wherein the lens is a porous hydrogel and the antibiotic or mycophenolic acid is within the pores of the hydrogel lens.

26. The article of claim 23 wherein the antibiotic or mycophenolic acid is in a coating on at least one lens surface.

27. The article of claim 23 wherein the lens is implanted in a lens capsule and the implanted lens releases the antibiotic or mycophenolic acid in the lens capsule.

28. An article comprising an implantable ocular lens in an ophthalmically acceptable medium, the medium further comprising an effective anti-cell proliferative or anti-cell migratory concentration of at least one macrolide antibiotic or mycophenolic acid.

29. The article of any of claims 22 or 28 wherein the concentration is in the range between about 20  $\mu\text{g}/\text{ml}$  to about 2000  $\mu\text{g}/\text{ml}$ .

30. The article of any of claims 22 or 28 wherein the concentration is in the range between about 200  $\mu\text{g}/\text{ml}$  to about 2000  $\mu\text{g}/\text{ml}$ .

31. The article of any of claims 22 or 28 wherein the concentration is in the range between about 20  $\mu\text{g}/\text{ml}$  to about 200  $\mu\text{g}/\text{ml}$ .

32. The article of any of claims 22, 23 or 28 wherein the macrolide antibiotic is at least one of tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, lincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide.

33. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the patient a composition comprising a concentration ranging between 0.5%<sup>WW</sup> to about 10%<sup>WW</sup> of a macrolide antibiotic and/or mycophenolic acid in a pharmaceutically acceptable topical formulation for a duration to achieve a concentration of the macrolide antibiotic and/or mycophenolic in a diseased ocular structure sufficient to treat the diseased eye.

34. The method of claim 33 wherein the diseased ocular structure is at least one of the choroid, retina, or uvea.
35. The method of claim 33 wherein the macrolide antibiotic is selected from at least one of tacrolimus, Cyclosporin A, sirolimus, ascomycin, and everolimus.
36. The method of claim 33 wherein the macrolide antibiotic is selected from at least one of erythromycin, azithromycin, clarithromycin, lincosycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, troleandomycin, roxithromycin, ABT-773, telithromycin, macrolides derived from leucomycins, and lincosamides.
37. The method of claim 33 wherein the composition is an extended-release formulation.
38. The method of claim 37 wherein the composition is provided on a contact lens or intraocular lens.
39. The method of claim 33 wherein the composition is formulated as at least one of a polymer, a microcapsule, a microsphere, a microvesicle, and a liposome.
40. The method of claim 33 for treating at least one of retinopathy, retinitis pigmentosa, age related macular degeneration, scleritis, uveitis, vasculitis, retinoblastoma, choroidal melanoma, and pre-malignant and malignant melanoma of the conjunctiva.
41. The method of claim 33 for administration to at least one of an ocular mucosal surface or the conjunctiva.
42. The method of claim 33 wherein the concentration of the macrolide antibiotic and/or mycophenolic acid is from at least one of about 0.5%<sup>w/v</sup> to about 3%<sup>w/v</sup>, about 3%<sup>w/v</sup> to about 5%<sup>w/v</sup>, about 5%<sup>w/v</sup> to about 10%<sup>w/v</sup>, or about 3%<sup>w/v</sup> to about 10%<sup>w/v</sup>.

43. The method of claim 33 for treating age related macular degeneration wherein the composition further comprises a cyclooxygenase inhibitor.

44. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the eye a composition consisting essentially of tacrolimus at a concentration from 0.5%<sup>w/v</sup> to about 10%<sup>w/v</sup> in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the structure.

45. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the eye a composition consisting essentially of Cyclosporin A at a concentration from 0.5%<sup>w/v</sup> to about 10%<sup>w/v</sup> in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the structure.

46. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the eye a composition consisting essentially of sirolimus at a concentration from 0.5%<sup>w/v</sup> to about 10%<sup>w/v</sup> in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the structure.

47. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the eye a composition consisting essentially of ascomycin at a concentration from 0.5%<sup>w/v</sup> to about 10%<sup>w/v</sup> in a pharmaceutically acceptable formulation for a duration sufficient to achieve a concentration in an internal ocular structure sufficient to treat the structure.

48. A non-invasive method to treat a diseased eye in a patient comprising topically administering to the eye a composition consisting essentially everolimus at a concentration from 0.5%<sup>w/v</sup> to about 10%<sup>w/v</sup> in a pharmaceutically acceptable formulation for a duration to achieve a concentration in an internal ocular structure sufficient to treat the structure.

49. The method of any of claims 44, 45, 46, 47, or 48 for treating at least one of retinopathy, retinitis pigmentosa, age related macular degeneration, uveitis, vasculitis, retinoblastoma, choroidal melanoma, and pre-malignant and malignant melanoma of the conjunctiva.

50. A topical ocular composition comprising at least one macrolide antibiotic and/or mycophenolic acid a concentration ranging from about 0.5%<sup>w/w</sup> to about 10%<sup>w/w</sup> and at least one of a polymer, a liposome, a microcapsule, and a microsphere in a pharmaceutically acceptable extended release topical ocular formulation.

51. The composition of claim 50 wherein the macrolide antibiotic is at least one of tacrolimus, cyclosporine, sirolimus, everolimus, ascomycin, erythromycin, azithromycin, clarithromycin, clindamycin, flincomycin, dirithromycin, josamycin, spiramycin, diacetyl-midecamycin, tylosin, roxithromycin, ABT-773, telithromycin, leucomycins, and lincosamide.

52. The composition of claim 50 provided with a contact lens or an intraocular lens.

53. The composition of claim 52 wherein the composition is on a lens surface.

54. The composition of claim 52 wherein the composition is contained in pores of a porous lens.

55. The composition of claim 50 further comprising at least one of a cyclooxygenase inhibitor or a chemotherapeutic agent.

56. An article comprising an ocular lens containing a concentration of at least one macrolide antibiotic and/or mycophenolic acid in a formulation to slowly release from the lens an intraocular concentration of the macrolide antibiotic and/or mycophenolic acid that does not exceed about 40 µg/ml.

57. The article of claim 56 wherein the intraocular concentration of macrolide antibiotic and/or mycophenolic acid ranges from about 10 µg/ml to about 30 µg/ml.

25

58. The article of claim 56 wherein the lens is a contact lens or an intraocular lens.

59. A non-invasive method to treat a diseased eye in a patient having diabetic retinopathy,

age related macular degeneration, or retinitis pigmentosa, the method comprising topically  
administering to the patient a composition comprising a concentration ranging between 0.1%<sup>WW</sup>

5 to about 10%<sup>WW</sup> of a macrolide antibiotic and/or mycophenolic acid in a pharmaceutically  
acceptable topical formulation for a duration to achieve a concentration of the macrolide antibiotic  
and/or mycophenolic in a diseased ocular structure sufficient to treat the diseased eye.

60. The method of claim 59 wherein the macrolide antibiotic and/or mycophenolic acid is  
formulated for extended release.

61. The method of claim 59 wherein the macrolide antibiotic and/or mycophenolic acid is  
provided with a contact lens or intraocular lens.

62. The method of claim 59 wherein the composition further comprises at least one  
cyclooxygenase inhibitor.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US2004/030186

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K31/436 A61K38/13 A61K31/365 A61K31/7048 A61K31/7052  
A61P27/02

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, EMBASE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2003/018044 A1 (PEYMAN GHOLAM A) 23 January 2003 (2003-01-23) page 2, column 1, paragraph 6 – page 4, column 1, paragraph 4; claims 1-30 -----	1-62
X	US 5 773 019 A (ASHTON ET AL) 30 June 1998 (1998-06-30) column 3, line 55 – line 65 column 6, line 8 – line 27; claims 12-22; example 5 -----	22-43, 45, 49-62
X	WO 03/017990 A2 (NOVARTIS AG; NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H; WONG,) 6 March 2003 (2003-03-06) page 1 – page 2; claims 1-10 -----	1-16, 33-55, 59-62 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

1 February 2005

08/02/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Markopoulos, E

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US2004/030186

C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/22722 A2 (ABBOTT LABORATORIES) 14 May 1999 (1999-05-14) page 3 - page 10 page 16 page 18 - page 19	33-55, 59-62
X	US 6 239 113 B1 (DAWSON CHANDLER R ET AL) 29 May 2001 (2001-05-29)  column 2, line 33 - line 59 column 4, line 54 - column 5, line 64 column 7, line 15 - column 8, line 48; claims 1-10	1-16, 33-55, 59-62
X	EP 0 532 862 A1 (UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC) 24 March 1993 (1993-03-24) column 3, line 30 - column 4, line 13 column 9, line 48 - line 51	33-55, 59-62
X	PATENT ABSTRACTS OF JAPAN vol. 1995, no. 04, 31 May 1995 (1995-05-31) & JP 07 010752 A (TOKUSHU MENEKI KENKYUSHO:KK), 13 January 1995 (1995-01-13) abstract	1-16, 33-49, 59-62
A	PATENT ABSTRACTS OF JAPAN vol. 1998, no. 04, 31 March 1998 (1998-03-31) & JP 09 315954 A (KITA:KK), 9 December 1997 (1997-12-09) abstract	1-62

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2004/030186

### Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 10-21, 33-49, 59-62 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 10-16,33-55,59-62

the use of macrolide antibiotics or mycophenolic acid in non-invasive treatment of eye diseases such as eye drops

2. claims: 1-32,56-58

the use of macrolide antibiotics or mycophenolic acid in invasive treatment of eye diseases such as implantable ocular lenses

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US2004/030186

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 2003018044	A1	23-01-2003	US 2002013340	A1	31-01-2002
US 5773019	A	30-06-1998	AT 284179	T	15-12-2004
			AU 717209	B2	23-03-2000
			AU 7371896	A	17-04-1997
			CA 2230947	A1	03-04-1997
			DE 69634009	D1	13-01-2005
			EP 0863729	A1	16-09-1998
			JP 11512711	T	02-11-1999
			US 6001386	A	14-12-1999
			WO 9711655	A1	03-04-1997
WO 03017990	A2	06-03-2003	BR 0211972	A	21-09-2004
			CA 2457034	A1	06-03-2003
			EP 1420787	A2	26-05-2004
			US 2003050255	A1	13-03-2003
WO 9922722	A2	14-05-1999	AU 1206799	A	24-05-1999
			BG 104436	A	29-12-2000
			BR 9813318	A	22-08-2000
			CA 2307850	A1	14-05-1999
			CN 1278178	T	27-12-2000
			EP 1027060	A2	16-08-2000
			HU 0100012	A2	28-05-2001
			JP 2001521891	T	13-11-2001
			NO 20002189	A	28-06-2000
			PL 340604	A1	12-02-2001
			SK 6172000	A3	12-03-2001
			TR 200001147	T2	21-08-2000
			ZA 9809885	A	05-05-1999
US 6239113	B1	29-05-2001	AU 772228	B2	22-04-2004
			AU 3920300	A	16-10-2000
			CA 2368637	A1	05-10-2000
			DE 1165058	T1	02-10-2002
			EP 1165058	A2	02-01-2002
			JP 2002540147	T	26-11-2002
			MX PA01009718	A	12-08-2002
			WO 0057866	A2	05-10-2000
			US 2002182255	A1	05-12-2002
			US 2003143259	A1	31-07-2003
			US 2003206956	A1	06-11-2003
			US 6569443	B1	27-05-2003
			US 2004266702	A1	30-12-2004
			ZA 200107454	A	10-09-2002
EP 0532862	A1	24-03-1993	AT 133336	T	15-02-1996
			AU 653415	B2	29-09-1994
			AU 2035092	A	28-01-1993
			CA 2074641	A1	26-01-1993
			CZ 9202307	A3	17-02-1993
			DE 69207847	D1	07-03-1996
			DE 69207847	T2	30-05-1996
			DK 532862	T3	19-02-1996
			ES 2083030	T3	01-04-1996
			HK 1005705	A1	22-01-1999
			HU 63763	A2	28-10-1993
			IE 922430	A1	27-01-1993

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International Application No  
PCT/US2004/030186

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0532862	A1	IL 102414 A		04-08-1996
		JP 2568962 B2		08-01-1997
		JP 5194212 A		03-08-1993
		KR 216768 B1		01-09-1999
		MX 9204381 A1		01-02-1993
		NZ 243679 A		24-06-1997
		SK 230792 A3		08-05-1996
		RU 2048812 C1		27-11-1995
		US 5387589 A		07-02-1995
		ZA 9204953 A		28-04-1993
JP 07010752	A	13-01-1995	NONE	
JP 09315954	A	09-12-1997	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

**BLACK BORDERS**

**IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

**FADED TEXT OR DRAWING**

**BLURRED OR ILLEGIBLE TEXT OR DRAWING**

**SKEWED/SLANTED IMAGES**

**COLOR OR BLACK AND WHITE PHOTOGRAPHS**

**GRAY SCALE DOCUMENTS**

**LINES OR MARKS ON ORIGINAL DOCUMENT**

**REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

**OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**